The C242T polymorphism of the p22-phox gene (CYBA) is associated with higher left ventricular mass in Brazilian hypertensive patients

BMC Medical Genetics

Volumn 12, Issue , 2011, Pages

  Schreiber, Roberto ^a   Ferreira Sae, Maria C ^a   Ronchi, Juliana A ^a   Pio Magalhães, José A ^a   Cipolli, José A ^a   Matos Souza, José R ^a   Mill, José G ^b   Vercesi, Aníbal E ^a   Krieger, José E ^c   Franchini, Kleber G ^a   Pereira, Alexandre C ^c   Nadruz Junior, Wilson ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hypertension; Left ventricle; NADPH oxidase; p22 phox; Polymorphism

Indexed keywords

PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; CYBA PROTEIN, HUMAN;

ADULT; AGE; ALLELE; ANTHROPOMETRY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; C242T POLYMORPHISM; CROSS-SECTIONAL STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; GENDER; GENETIC POLYMORPHISM; GENOTYPE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; PHYSICAL EXAMINATION; BLOOD; BRAZIL; CLINICAL TRIAL; ENZYMOLOGY; GENE FREQUENCY; GENETICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; BRAZIL; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NADPH OXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; VENTRICULAR REMODELING;

EID: 80052175971     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-12-114     Document Type: Article

References (30)

1. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 2008, 21:500-508. 10.1038/ajh.2008.16, 18437140.
2. Maytin M, Siwik DA, Ito M, Xiao L, Sawyer DB, Liao R, Colucci WS. Pressure overload-induced myocardial hypertrophy in mice does not require gp91phox. Circulation 2004, 109:1168-1171. 10.1161/01.CIR.0000117229.60628.2F, 14981002.
3. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006, 71:208-215. 10.1016/j.cardiores.2006.03.016, 16631149.
4. Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, Brandes RP. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 2004, 279:45935-45941. 10.1074/jbc.M406486200, 15322091.
5. Nadruz W, Lagosta VJ, Moreno H, Coelho OR, Franchini KG. Simvastatin prevents load-induced protein tyrosine nitration in overloaded hearts. Hypertension 2004, 43:1060-1066. 10.1161/01.HYP.0000124252.43470.2c, 15023931.
6. Zalba G, San José G, Moreno MU, Fortuño A, Díez J. NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension. Antioxid Redox Signal 2005, 7:1327-1336. 10.1089/ars.2005.7.1327, 16115038.
7. Dinauer MC, Pierce EA, Bruns GA, Curnutte JT, Orkin SH. Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J Clin Invest 1990, 86:1729-1737. 10.1172/JCI114898, 296926, 2243141.
8. Shimo-Nakanishi Y, Hasebe T, Suzuki A, Mochizuki H, Nomiyama T, Tanaka Y, Nagaoka I, Mizuno Y, Urabe T. Functional effects of NAD(P)H oxidase p22(phox) C242T mutation in human leukocytes and association with thrombotic cerebral infarction. Atherosclerosis 2004, 175:109-115. 10.1016/j.atherosclerosis.2004.01.043, 15186954.
9. San José G, Fortuño A, Beloqui O, Díez J, Zalba G. NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. Clin Sci 2008, 114:173-182. 10.1042/CS20070130, 18184111.
10. Di Castelnuovo A, Soccio M, Iacoviello L, Evangelista V, Consoli A, Vanuzzo D, Diviacco S, Carluccio M, Rignanese L, De Caterina R. The C242T polymorphism of the p22phox component of NAD(P)H oxidase and vascular risk. Two case-control studies and a meta-analysis. Thromb Haemost 2008, 99:594-601.
11. Sales ML, Schreiber R, Ferreira-Sae MC, Fernandes MN, Piveta C, Cipolli JA, Calixto A, Matos-Souza JR, Geloneze B, Franchini KG, Nadruz W. The functional Toll-like receptor 4 Asp299Gly polymorphism is associated with lower left ventricular mass in hypertensive women. Clin Chim Acta 2010, 411:744-748. 10.1016/j.cca.2010.02.006, 20146922.
12. Sales ML, Schreiber R, Ferreira-Sae MC, Fernandes MN, Piveta CS, Cipolli JA, Cardoso CC, Matos-Souza JR, Geloneze B, Franchini KG, Nadruz W. Toll-like Receptor 6 Ser249Pro polymorphism is associated with lower left ventricular wall thickness and inflammatory response in hypertensive women. Am J Hypertens 2010, 23:649-654. 10.1038/ajh.2010.24, 20224557.
13. Pereira AC, Pereira AB, Mota GF, Cunha RS, Herkenhoff FL, Pollak MR, Mill JG, Krieger JE. NPHS2 R229Q functional variant is associated with microalbuminuria in the general population. Kidney Int 2004, 65:1026-1030. 10.1111/j.1523-1755.2004.00479.x, 14871423.
14. Executive Summary: The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702.
15. Pio-Magalhães JA, Cornélio M, Leme CA, Matos-Souza JR, Garlipp CR, Gallani MC, Rodrigues RC, Franchini KG, Nadruz W. Upper arm circumference is an independent predictor of left ventricular concentric hypertrophy in hypertensive women. Hypertens Res 2008, 31:1177-1183. 10.1291/hypres.31.1177, 18716366.
16. Cipolli JA, Souza FA, Ferreira-Sae MC, Pio-Magalhães JA, Figueiredo ES, Vidotti VG, Matos-Souza JR, Franchini KG, Nadruz W. Sex-specific hemodynamic and non-hemodynamic determinants of aortic root size in hypertensive subjects with left ventricular hypertrophy. Hypertens Res 2009, 32:956-961. 10.1038/hr.2009.134, 19713970.
17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W, , , . American Society of Echocardiography's Nomenclature and Standards Committee, Task Force on Chamber Quantification, American College of Cardiology Echocardiography Committee, American Heart Association, European Association of Echocardiography, European Society of Cardiology Recommendations for chamber quantification. Eur J Echocardiogr 2006, 7:79-108. 10.1016/j.euje.2005.12.014, 16458610, American Society of Echocardiography's Nomenclature and Standards Committee, Task Force on Chamber Quantification, American College of Cardiology Echocardiography Committee, American Heart Association, European Association of Echocardiography, European Society of Cardiology.
18. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998, 97:135-137.
19. Degasperi GR, Denis RGP, Morari J, Solon C, Geloneze B, Stabe C, Pareja JC, Vercesi AE, Velloso LA. Reactive oxygen species production is increased in the peripheral blood monocytes of obese patients. Metabolism 2009, 58:1087-1095. 10.1016/j.metabol.2009.04.002, 19439330.
20. Cahilly C, Ballantyne CM, Lim DS, Gotto A, Marian AJ. A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res 2000, 86:391-395.
21. Ito D, Murata M, Watanabe K, Yoshida T, Saito I, Tanahashi N, Fukuuchi Y. C242T polymorphism of NADPH oxidase p22 PHOX gene and ischemic cerebrovascular disease in the Japanese population. Stroke 2000, 31:936-939. 10.1161/01.STR.31.4.936, 10754002.
22. Kim KI, Na JE, Kang SY, Cho YS, Choi DJ, Kim CH, Kim HS, Oh BH, Choi YH, Kwon IS, Park SC. Impact of NAD(P)H oxidase p22 phox gene polymorphism on vascular aging in Korean centenarian and nonagenarian. Int J Cardiol 2007, 123:18-22. 10.1016/j.ijcard.2006.11.105, 17307262.
23. Li A, Prasad A, Mincemoyer R, Satorius C, Epstein N, Finkel T, Quyyumi AA. Relationship of the C242T p22phox gene polymorphism to angiographic coronary artery disease and endothelial function. Am J Med Genet 1999, 86:57-61. 10.1002/(SICI)1096-8628(19990903)86:1<57::AID-AJMG11>3.0.CO;2-R, 10440830.
24. Fan M, Kähönen M, Rontu R, Lehtinen R, Viik J, Niemi M, Nieminen T, Niemelä K, Pörsti I, Kööbi T, Turjanmaa V, Lehtimäki T. The p22phox C242T gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in a high-risk Finnish Caucasian population. The Finnish Cardiovascular Study. Am Heart J 2006, 152:538-542. 10.1016/j.ahj.2006.02.018, 16923427.
25. Hayaishi-Okano R, Yamasaki Y, Kajimoto Y, Sakamoto K, Ohtoshi K, Katakami N, Kawamori D, Miyatsuka T, Hatazaki M, Hazama Y, Hori M. Association of NAD(P)H oxidase p22 phox gene variation with advanced carotid atherosclerosis in Japanese type 2 diabetes. Diabetes Care 2003, 26:458-463. 10.2337/diacare.26.2.458, 12547880.
26. Moreno MU, San Jose G, Fortuño A, Beloqui O, Diez J, Zalba G. The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. J Hypertens 2006, 24:1299-1306. 10.1097/01.hjh.0000234110.54110.56, 16794479.
27. Sales ML, Ferreira MC, Leme CA, Velloso LA, Gallani MC, Colombo RC, Franchini KG, Nadruz W. Non-effect of p22-phox -930A/G polymorphism on end-organ damage in Brazilian hypertensive patients. J Hum Hypertens 2007, 21:504-506.
28. Wyche KE, Wang SS, Griendling KK, Dikalov SI, Austin H, Rao S, Fink B, Harrison DG, Zafari AM. C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils. Hypertension 2004, 43:1246-1251. 10.1161/01.HYP.0000126579.50711.62, 15078863.
29. Wang Y, Biswas G, Prabu SK, Avadhani NG. Modulation of mitochondrial metabolic function by phorbol 12-myristate 13-acetate through increased mitochondrial translocation of protein kinase Calpha in C2C12 myocytes. Biochem Pharmacol 2006, 72:881-892. 10.1016/j.bcp.2006.06.032, 16899228.
30. Yang M, Foster E, Kahn AM. Insulin-stimulated NAD(P)H oxidase activity increases migration of cultured vascular smooth muscle cells. Am J Hypertens 2005, 18:1329-1334. 10.1016/j.amjhyper.2005.04.012, 16202857.